JP2019533690A5 - - Google Patents

Download PDF

Info

Publication number
JP2019533690A5
JP2019533690A5 JP2019522771A JP2019522771A JP2019533690A5 JP 2019533690 A5 JP2019533690 A5 JP 2019533690A5 JP 2019522771 A JP2019522771 A JP 2019522771A JP 2019522771 A JP2019522771 A JP 2019522771A JP 2019533690 A5 JP2019533690 A5 JP 2019533690A5
Authority
JP
Japan
Prior art keywords
cancer
tumor
arenavirus
antigen
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019522771A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019533690A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/078149 external-priority patent/WO2018083220A2/en
Publication of JP2019533690A publication Critical patent/JP2019533690A/ja
Publication of JP2019533690A5 publication Critical patent/JP2019533690A5/ja
Priority to JP2022188395A priority Critical patent/JP2023029898A/ja
Withdrawn legal-status Critical Current

Links

JP2019522771A 2016-11-04 2017-11-03 癌ワクチンとしての複製欠損性アレナウイルス粒子及び3セグメント型アレナウイルス粒子 Withdrawn JP2019533690A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022188395A JP2023029898A (ja) 2016-11-04 2022-11-25 癌ワクチンとしての複製欠損性アレナウイルス粒子及び3セグメント型アレナウイルス粒子

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662417865P 2016-11-04 2016-11-04
US201662417891P 2016-11-04 2016-11-04
US62/417,891 2016-11-04
US62/417,865 2016-11-04
PCT/EP2017/078149 WO2018083220A2 (en) 2016-11-04 2017-11-03 Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022188395A Division JP2023029898A (ja) 2016-11-04 2022-11-25 癌ワクチンとしての複製欠損性アレナウイルス粒子及び3セグメント型アレナウイルス粒子

Publications (2)

Publication Number Publication Date
JP2019533690A JP2019533690A (ja) 2019-11-21
JP2019533690A5 true JP2019533690A5 (enExample) 2020-12-17

Family

ID=60452580

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019522771A Withdrawn JP2019533690A (ja) 2016-11-04 2017-11-03 癌ワクチンとしての複製欠損性アレナウイルス粒子及び3セグメント型アレナウイルス粒子
JP2022188395A Pending JP2023029898A (ja) 2016-11-04 2022-11-25 癌ワクチンとしての複製欠損性アレナウイルス粒子及び3セグメント型アレナウイルス粒子

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022188395A Pending JP2023029898A (ja) 2016-11-04 2022-11-25 癌ワクチンとしての複製欠損性アレナウイルス粒子及び3セグメント型アレナウイルス粒子

Country Status (7)

Country Link
US (2) US20200206334A1 (enExample)
EP (1) EP3534943A2 (enExample)
JP (2) JP2019533690A (enExample)
CN (1) CN110167586B (enExample)
AU (1) AU2017353443B2 (enExample)
CA (1) CA3039356A1 (enExample)
WO (1) WO2018083220A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103993012B (zh) 2007-12-27 2023-01-10 苏黎士大学 复制缺陷型沙粒病毒载体
RS61993B1 (sr) 2013-12-03 2021-07-30 Hookipa Biotech Gmbh Cmv vakcine
ES2811093T3 (es) 2014-11-13 2021-03-10 Univ Geneve Arenavirus trisegmentados como vectores de vacunas
HK1246183A1 (zh) 2015-06-10 2018-09-07 Hookipa Biotech Gmbh Hpv疫苗
WO2017076988A1 (en) 2015-11-04 2017-05-11 Hookipa Biotech Ag Vaccines against hepatitis b virus
EP3373959B1 (en) 2015-11-12 2022-06-29 Hookipa Biotech GmbH Arenavirus particles as cancer vaccines
MX2019009070A (es) 2017-02-01 2019-10-30 Modernatx Inc Composiciones de arnm terapeuticas inmunomoduladoras que codifican peptidos de mutacion de oncogenes de activacion.
CN110719788A (zh) * 2017-04-07 2020-01-21 霍欧奇帕生物科技有限公司 治疗实体瘤的沙粒病毒颗粒
DE102018215551A1 (de) 2018-09-12 2020-03-12 Virolutions Biotech Gmbh Verfahren zur Herstellung eines antitumoralen Arenavirus sowie Arenavirusmutanten
MX2023011054A (es) 2021-03-23 2023-11-22 Hookipa Biotech Gmbh Arenavirus utilizados en tratamientos del cáncer de próstata.
US20250073324A1 (en) * 2021-11-08 2025-03-06 Hookipa Biotech Gmbh Modified arenavirus particles expressing mutant kras, mutated cancer driver gene, or tumor-associated antigen as cancer immunotherapies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
CA2646891A1 (en) 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
ATE539079T1 (de) 2006-03-23 2012-01-15 Novartis Ag Imidazochinoxalinverbindungen als immunmodulatoren
CN103993012B (zh) 2007-12-27 2023-01-10 苏黎士大学 复制缺陷型沙粒病毒载体
US9809801B2 (en) 2013-03-15 2017-11-07 Université De Genève Anti-mycobacterial vaccines
RS61993B1 (sr) 2013-12-03 2021-07-30 Hookipa Biotech Gmbh Cmv vakcine
ES2811093T3 (es) * 2014-11-13 2021-03-10 Univ Geneve Arenavirus trisegmentados como vectores de vacunas
HK1246183A1 (zh) * 2015-06-10 2018-09-07 Hookipa Biotech Gmbh Hpv疫苗

Similar Documents

Publication Publication Date Title
JP2023029898A5 (enExample)
JP7506030B2 (ja) 適応免疫応答を誘導するためのヌクレオシド修飾rna
JP7157662B2 (ja) 癌ワクチンとしてのアレナウイルス粒子
JP2023029898A (ja) 癌ワクチンとしての複製欠損性アレナウイルス粒子及び3セグメント型アレナウイルス粒子
JP2018533604A5 (enExample)
TWI780069B (zh) 用於病毒專一性t細胞之活化及增生的平台
US20200113995A1 (en) Arenavirus particles to treat solid tumors
Russell Replicating vectors for gene therapy of cancer: risks, limitations and prospects
EP4141111A1 (en) Oncolytic virus vaccine and drug for treating tumors by combining oncolytic virus vaccine with immune cells
JP2021176314A (ja) 修飾されたtリンパ球
JPWO2017209053A1 (ja) 新規な遺伝子組換えワクシニアウイルス
WO2022188764A1 (zh) 一种低表达cd7的nk细胞制备方法
AU2013204923A1 (en) Modified t lymphocytes having improved specificity
US7270812B2 (en) Pharmaceutical composition for treatment of cancers
US12558417B2 (en) Hepatitis A virus preparation method and hepatitis A virus prepared according to method
WO2025131084A1 (en) Use of dr-18 and m1 virus in preparation of anti-tumor drug
US20240245765A1 (en) Use of Ectromelia Virus for Cancer Immunotherapy and Vaccines
Guinn et al. International society for cell and gene therapy of cancer (ISCGT) annual meeting: conference overview and introduction to the symposium papers
Weigel-Van Aken Cancer Gene Therapy
HK1260579A1 (en) Arenavirus particles as cancer vaccines
HK1260579B (en) Arenavirus particles as cancer vaccines